Translational Development Acquisition Corp.
TDAC
$10.72
$0.010.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 73.26% | -24.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 73.26% | -24.05% | |||
| Operating Income | -73.26% | 24.05% | |||
| Income Before Tax | -16.49% | -3.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.49% | -3.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.49% | -3.87% | |||
| EBIT | -73.26% | 24.05% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 293.13% | -3.96% | |||
| Normalized Basic EPS | 325.95% | -11.39% | |||
| EPS Diluted | 293.13% | -3.96% | |||
| Normalized Diluted EPS | 325.95% | -11.39% | |||
| Average Basic Shares Outstanding | -78.74% | 0.00% | |||
| Average Diluted Shares Outstanding | -78.74% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||